The company received FDA clearance for a Phase 3b trial (ENDURANCE) designed to support a potential BLA submission, planning to enroll approximately 200 participants. In February 2026, BrainStorm raised $2 million in strategic private placements to advance its regulatory and clinical objectives.
Cyborg Score Rationale
The company delisted from Nasdaq in July 2025 due to non-compliance with equity requirements and transitioned to OTCQB. Cash position was critically low at $0.23 million as of Q3 2025. However, recent funding raises and FDA-cleared Phase 3b trial provide near-term catalysts.
Top Insights
Expanded Access Program showed 100% of participants surviving beyond 5 years from ALS symptom onset with median survival of 6.8 years, providing compelling efficacy signals.
Delisted from Nasdaq to OTCQB in July 2025 due to shareholder equity requirements non-compliance.
Completed Phase 2 open-label trial in progressive multiple sclerosis supported by National MS Society grant.
Developing proprietary allogeneic exosome platform with foundational patent allowance from USPTO for emerging IP portfolio.
Named Competitors
Autologous Stem Cell Therapies — Cell therapy competitors in neurodegenerative space
ALS Therapeutics Pipeline — Traditional small molecule and biologic ALS treatments
Recent Developments
(February 2026) Secured $2 million in strategic private placements at $0.60 per share with 120% warrant coverage
(November 2025) FDA cleared Phase 3b ENDURANCE trial for NurOwn in ALS; ALS community filed Citizen Petition for regulatory re-evaluation
(July 2025) Delisted from Nasdaq Capital Market, transitioned to OTCQB due to shareholder equity non-compliance
Open the full interactive BrainStorm Cell Therapeutics Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.